Skin Diseases  >>  Arcalyst (rilonacept)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Arcalyst (rilonacept) / Regeneron, Kiniksa
NCT00094900: Interleukin-1 Trap to Treat Autoinflammatory Diseases

Completed
2
11
US
IL-1 Trap
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset
09/10
12/10
ACCILTRA1, NCT01045772 / 2006-004290-97: Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)

Completed
2
10
Europe
rilonacept, Arcalyst
Charite University, Berlin, Germany
Muckle-Wells Syndrome, Schnitzler Syndrome
09/10
09/10
NCT00582907: Rilonacept for Treatment of Familial Mediterranean Fever (FMF)

Completed
2
14
US
Rilonacept, Arcalyst, IL-1 Trap, Placebo
The Cleveland Clinic
Familial Mediterranean Fever
09/11
09/11
NCT01801449: Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)

Completed
2
6
US
Rilonacept
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health Clinical Center (CC)
DIRA
04/16
04/16
NCT02171416 / 2012-005726-30: Cold Contact Urticaria Treatment With Rilonacept

Completed
2
20
Europe
Rilonacept, Arcalyst, Placebo
Charite University, Berlin, Germany, Regeneron Pharmaceuticals
Cold Contact Urticaria
02/18
05/18
NCT01538719: IL1-TRAP, Rilonacept, in Systemic Sclerosis

Completed
1/2
24
US
Rilonacept, IL1-TRAP, Placebo
Boston University, Regeneron Pharmaceuticals
Scleroderma, Systemic Sclerosis, Diffuse Scleroderma, Diffuse Systemic Sclerosis
01/17
08/17

Download Options